Статті в журналах з теми "EML4-ALK fusion protein"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 статей у журналах для дослідження на тему "EML4-ALK fusion protein".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
Richards, Mark W., Laura O'Regan, Daniel Roth, Jessica M. Montgomery, Anne Straube, Andrew M. Fry, and Richard Bayliss. "Microtubule association of EML proteins and the EML4-ALK variant 3 oncoprotein require an N-terminal trimerization domain." Biochemical Journal 467, no. 3 (April 17, 2015): 529–36. http://dx.doi.org/10.1042/bj20150039.
Повний текст джерелаMao, Weimin, Mark Han, Zhiqiang Ling, Wenyong Sun, Gu Zhang, Hongshan Dong, and Yingzi Zhang. "Triple probe FISH approach for detecting EML4-ALK gene rearrangement in Chinese patients with NSCLC." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): e21080-e21080. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e21080.
Повний текст джерелаPapadopoulou, Eirini, Samuel Murray, and George Nasioulas. "Development of a novel RT-PCR assay for the detection of EML4-ALK fusion products in FFPE speciments." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): e21087-e21087. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e21087.
Повний текст джерелаSu, Kang-Yi, Bing-Ching Ho, Gee-Chen Chang, Hsuan-Yu Chen, Pan-Chyr Yang, and Sung-Liang Yu. "Multiplex ALK, RET, and ROS1 fusion mutation detection in FFPE from lung cancer patients by MALDI-TOF mass spectrometry." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): e13103-e13103. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e13103.
Повний текст джерелаGonzalez-Martinez, David, Lee Roth, Thomas Mumford, Yael Mosse, Asmin Tulpule, Trever Bivona, and Lukasz Jan Bugaj. "Abstract 848: Inhibition of RTK fusion condensates enhances signal perception and promotes drug tolerance." Cancer Research 82, no. 12_Supplement (June 15, 2022): 848. http://dx.doi.org/10.1158/1538-7445.am2022-848.
Повний текст джерелаMehta, Anurag, and Ullas Batra. "Molecular epidemiological study of microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene using immunohistochemistry as a cost effective alternative to fluorescence in situ hybridization for Indian patients with adenocarcinoma lung." Asian Journal of Oncology 03, no. 01 (January 2017): 045–49. http://dx.doi.org/10.4103/asjo.asjo_116_16.
Повний текст джерелаXiang, Yan, Shiyu Zhang, Xiaoxu Fang, Yingying Jiang, Tingwen Fang, Jinwen Liu, and Kaihua Lu. "Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer." Current Oncology 29, no. 10 (October 16, 2022): 7816–31. http://dx.doi.org/10.3390/curroncol29100618.
Повний текст джерелаMaus, Martin Karl Herbert, Craig Stephens, Gary Zeger, Peter Philipp Grimminger, and Eric Huang. "Identification of novel variant of EML4-ALK fusion gene in NSCLC: Potential benefits of the RT-PCR method." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): e12007-e12007. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e12007.
Повний текст джерелаPapageorgiou, Savvas, Sarah L. Pashley, Laura O’Regan, Sam Khan, Richard Bayliss, and Andrew M. Fry. "Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer." Cancers 14, no. 14 (July 15, 2022): 3452. http://dx.doi.org/10.3390/cancers14143452.
Повний текст джерелаHochmair, Maximilian J., Ulrike Setinek, Thomas Efstathiades, Klaus Kirchbacher, Andrea Mohn-Staudner, Britt-Madeleine Arns, Melina Gulesserian, et al. "EML4-ALK mutation in Austrian patients with NSCLC: A multicenter study." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): e19093-e19093. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e19093.
Повний текст джерелаHeuckmann, Johannes M., Hyatt Balke-Want, Florian Malchers, Martin Peifer, Martin L. Sos, Mirjam Koker, Lydia Meder, et al. "Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants." Clinical Cancer Research 18, no. 17 (August 21, 2012): 4682–90. http://dx.doi.org/10.1158/1078-0432.ccr-11-3260.
Повний текст джерелаHsiao, Sheng-Yen, Hong-Lin He, Teng-Song Weng, Cheng-Yao Lin, Chien-Ming Chao, Wen-Tsung Huang, and Chao-Jung Tsao. "Colorectal Cancer with EML4-ALK Fusion Gene Response to Alectinib: A Case Report and Review of the Literature." Case Reports in Oncology 14, no. 1 (March 1, 2021): 232–38. http://dx.doi.org/10.1159/000511069.
Повний текст джерелаWangsiricharoen, Sintawat, Minghao Zhong, Sarangarajan Ranganathan, Andres Matoso, and Pedram Argani. "ALK-rearranged Renal Cell Carcinoma (RCC): A Report of 2 Cases and Review of the Literature Emphasizing the Distinction Between VCL-ALK and Non-VCL-ALK RCC." International Journal of Surgical Pathology 29, no. 7 (March 17, 2021): 808–14. http://dx.doi.org/10.1177/10668969211003660.
Повний текст джерелаCampos-Gomez, Saul, Humberto Lara-Guerra, Mark J. Routbort, Xinyan Lu, and George R. Simon. "Lung adenocarcinoma with Concurrent KRAS Mutation and ALK Rearrangement Responding to Crizotinib: Case Report." International Journal of Biological Markers 30, no. 2 (April 2015): 254–57. http://dx.doi.org/10.5301/jbm.5000127.
Повний текст джерелаBatra, Ullas, Mohit Aggarwal, Parveen Jain, Pankaj Goyal, Abhishek Yadav, Udip Maheshwari, and Anurag Mehta. "Clinical outcome study of crizotinib in immunohistochemistry-proven echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene among Indian patients with adenocarcinoma lung." South Asian Journal of Cancer 07, no. 01 (January 2018): 61–64. http://dx.doi.org/10.4103/sajc.sajc_215_17.
Повний текст джерелаHui, Beina, Jingping Zhang, Xiaobo Shi, Fangfang Xing, Yang W. Shao, Yuanyuan Wang, Xiaozhi Zhang, and Shuwen Wang. "EML4-ALK, a potential therapeutic target that responds to alectinib in ovarian cancer." Japanese Journal of Clinical Oncology 50, no. 12 (August 26, 2020): 1470–74. http://dx.doi.org/10.1093/jjco/hyaa156.
Повний текст джерелаSugiyama, Keiji, Ai Izumika, Akari Iwakoshi, Riko Nishibori, Mariko Sato, Kazuhiro Shiraishi, Hiroyoshi Hattori, Rieko Nishimura, and Chiyoe Kitagawa. "Successful Alectinib Treatment for Carcinoma of Unknown Primary with EML4-ALK Fusion Gene: A Case Report." Current Oncology 28, no. 3 (May 21, 2021): 1938–45. http://dx.doi.org/10.3390/curroncol28030180.
Повний текст джерелаShafik, Hanan Ezzat, and Mohamed Ashour. "Frequency of EGFR Mutation and EML4-ALK fusion gene in Arab Patients with Adenocarcinoma of the Lung." Forum of Clinical Oncology 6, no. 2 (June 1, 2015): 19–23. http://dx.doi.org/10.1515/fco-2015-0009.
Повний текст джерелаHuo, Yinping, Tangfeng Lv, Mingxiang Ye, Suhua Zhu, Jiaxin Liu, Hongbing Liu, and Yong Song. "F-circEA1 regulates cell proliferation and apoptosis through ALK downstream signaling pathway in non-small cell lung cancer." Human Cell 35, no. 1 (October 11, 2021): 260–70. http://dx.doi.org/10.1007/s13577-021-00628-7.
Повний текст джерелаHu, Wanming, Li Yuan, and Jing Zeng. "PATH-01. Infant-Type Hemispheric Glioma: New Molecular Alterations and Precision-Medicine Treatment." Neuro-Oncology 24, Supplement_1 (June 1, 2022): i157—i158. http://dx.doi.org/10.1093/neuonc/noac079.585.
Повний текст джерелаKimura, Tatsuo, Junko Sowa-Osako, Toshiyuki Nakai, Ayako Ohyama, Tomoya Kawaguchi, Daisuke Tsuruta, Masahiko Ohsawa, and Kazuto Hirata. "Alectinib-Induced Erythema Multiforme and Successful Rechallenge with Alectinib in a Patient with Anaplastic Lymphoma Kinase-Rearranged Lung Cancer." Case Reports in Oncology 9, no. 3 (December 8, 2016): 826–32. http://dx.doi.org/10.1159/000453314.
Повний текст джерелаShin, Miyoung, Paris Petersen, Steven Lau-Rivera, Segun Jung, Sally Agersborg, Jacyln Hechtman, Fernando Lopez-Diaz, and Vincent Funari. "Abstract 1254: Actionable fusions detected by RNA-seq co-occur with PD-L1 expression and driver mutations in solid tumors patients." Cancer Research 82, no. 12_Supplement (June 15, 2022): 1254. http://dx.doi.org/10.1158/1538-7445.am2022-1254.
Повний текст джерелаLuo, Lian-Xiang, Ying Li, Yu-Zhen Niu, Yu-Wei Wang, Qian-Qian Wang, Xing-Xing Fan, Jia-Hui Xu, Liang Liu, Elaine Lai-Han Leung, and Xiao-Jun Yao. "Identification of a potent kinase inhibitor targeting EML4-ALK fusion protein in non-small cell lung cancer." MedChemComm 8, no. 10 (2017): 1914–18. http://dx.doi.org/10.1039/c7md00305f.
Повний текст джерелаWang, Dandan, Daixi Li, Guangrong Qin, Wen Zhang, Jian Ouyang, Menghuan Zhang, and Lu Xie. "The Structural Characterization of Tumor Fusion Genes and Proteins." Computational and Mathematical Methods in Medicine 2015 (2015): 1–9. http://dx.doi.org/10.1155/2015/912742.
Повний текст джерелаSingh, Randeep, and Nitesh Rohtagi. "Clinicopathological and molecular epidemiological study of lung cancer patients seen at a tertiary care hospital in Northern India." South Asian Journal of Cancer 06, no. 04 (October 2017): 171–75. http://dx.doi.org/10.4103/sajc.sajc_63_17.
Повний текст джерелаMiller, Jill, Zhihua Peng, Rebecca Wilcox, Mark Evans, Kumarasen Cooper, Steven Ades, and Claire F. Verschraegen. "Investigation of anaplastic lymphoma kinase (ALK) translocations in gastric and esophageal signet ring cell carcinomas." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): e15106-e15106. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e15106.
Повний текст джерелаWang, Wen Xian, Chun-Wei Xu, Ziming Li, Zhengbo Song, Wenfeng Fang, Liyun Miao, You-Cai Zhu, et al. "Chinese advanced fusion-dependent lung cancer patients: Molecular spectrum and treatment options using next generation sequencing—A multicenter study (Yangtze River Delta Lung Cancer Cooperation Group-001)." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): e21036-e21036. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e21036.
Повний текст джерелаSozzi, G., M. P. Martelli, D. Conte, P. Modena, V. Pettirossi, S. A. Pileri, and B. Falini. "The EML4-ALK transcript but not the fusion protein can be expressed in reactive and neoplastic lymphoid tissues." Haematologica 94, no. 9 (September 1, 2009): 1307–11. http://dx.doi.org/10.3324/haematol.2009.008045.
Повний текст джерелаRybarczyk-Kasiuchnicz, Agnieszka, Rodryg Ramlau, and Katarzyna Stencel. "Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma." International Journal of Molecular Sciences 22, no. 2 (January 8, 2021): 593. http://dx.doi.org/10.3390/ijms22020593.
Повний текст джерелаRybarczyk-Kasiuchnicz, Agnieszka, Rodryg Ramlau, and Katarzyna Stencel. "Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma." International Journal of Molecular Sciences 22, no. 2 (January 8, 2021): 593. http://dx.doi.org/10.3390/ijms22020593.
Повний текст джерелаKawamura, Takahisa, Haruyasu Murakami, Haruki Kobayashi, Kazuhisa Nakashima, Shota Omori, Kazushige Wakuda, Akira Ono, et al. "Leptomeningeal recurrence after long-term alectinib therapy for non-small cell lung cancer harboring an EML4-ALK fusion protein." Investigational New Drugs 37, no. 1 (July 3, 2018): 184–87. http://dx.doi.org/10.1007/s10637-018-0633-6.
Повний текст джерелаChen, Nan, and Robert C. Doebele. "Abstract 1100: miR205 mediates acquired resistance to ALK inhibition via targeting Mig6 expression and enhancing EGFR signaling." Cancer Research 82, no. 12_Supplement (June 15, 2022): 1100. http://dx.doi.org/10.1158/1538-7445.am2022-1100.
Повний текст джерелаKhthir, Rodhan, Zainab Shaheen, Prasanna Santhanam, and Saroj Sigdel. "Aggressive Differentiated Thyroid Cancer due to EML4e13-ALKe20 Fusion: A Case Presentation and Review of the Literature." Case Reports in Endocrinology 2021 (February 15, 2021): 1–7. http://dx.doi.org/10.1155/2021/8837399.
Повний текст джерелаOkimoto, Tamio, Yukari Tsubata, Takamasa Hotta, Megumi Hamaguchi, Takae Okuno, Yohei Shiratsuki, Akari Kodama, et al. "Successful rechallenge with ceritinib after leukocytoclastic vasculitis during ceritinib treatment for non-small cell lung cancer harboring the EML4-ALK fusion protein." Oncotarget 9, no. 28 (April 13, 2018): 20213–18. http://dx.doi.org/10.18632/oncotarget.24765.
Повний текст джерелаRamshankar, Vijayalakshmi, Subha Yegnaswamy, Kumarasamy P, and Krishnamurthy Arvind. "Molecular docking studies shows tivozanib and lapatinib as potential inhibitors of EML4-ALK translocation mediated fusion protein in non small cell lung cancer." Bioinformation 10, no. 10 (October 30, 2014): 658–63. http://dx.doi.org/10.6026/97320630010658.
Повний текст джерелаHong, Shaodong, Nan Chen, Wenfeng Fang, Jianhua Zhan, Qing Liu, Shiyang Kang, Xiaobo He, et al. "Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients." OncoImmunology 5, no. 3 (December 21, 2015): e1094598. http://dx.doi.org/10.1080/2162402x.2015.1094598.
Повний текст джерелаTyler, Logan C., Nan Chen, Anh T. Le, Hala Nijmeh, Liming Bao, and Robert C. Doebele. "Abstract 1102: Fyn and Src cooperate with ERBB family to drive resistance to crizotinib in ROS1+ and ALK+ NSCLC." Cancer Research 82, no. 12_Supplement (June 15, 2022): 1102. http://dx.doi.org/10.1158/1538-7445.am2022-1102.
Повний текст джерелаFarhood, Rawaa Ghalib, Kaswer Al-tariahi, Rehab Hameed Adul-Sahieb, and Afraa Mamoori. "Detection of EML4-ALK Fusion Gene Rearrangement in Non-Small Cell Lung Carcinoma in a Sample of Iraqi Patients: A Comparison of Chromogenic in Situ Hybridization with Correlation of ALK Protein Expression." Indian Journal of Public Health Research & Development 10, no. 5 (2019): 1267. http://dx.doi.org/10.5958/0976-5506.2019.01170.7.
Повний текст джерелаYang, Xiaojuan, Diyuan Qin, Yu Zhang, Xue Li, Ning Liu, Ying Zhou, Ming Feng, and Yongsheng Wang. "An elderly female patient with ROS1 rearrangement primary lung adenocarcinoma and breast carcinoma: a rare case report and review of the literature." Precision Clinical Medicine 2, no. 3 (August 28, 2019): 197–203. http://dx.doi.org/10.1093/pcmedi/pbz013.
Повний текст джерелаKumar, Pragya, Virginia Turati, and Andriy Marusyk. "Abstract B032: Deciphering the mechanisms of environmentally mediated Alectinib resistance in ALK+NSCLC." Cancer Research 82, no. 10_Supplement (May 15, 2022): B032. http://dx.doi.org/10.1158/1538-7445.evodyn22-b032.
Повний текст джерелаFoltz, Steven M., Qingsong Gao, Christopher J. Yoon, Amila Weerasinghe, Hua Sun, Lijun Yao, Mark A. Fiala, et al. "Comprehensive Multi-Omics Analysis of Gene Fusions in a Large Multiple Myeloma Cohort." Blood 132, Supplement 1 (November 29, 2018): 1898. http://dx.doi.org/10.1182/blood-2018-99-117245.
Повний текст джерелаRossi, Elisabetta, Michele Aieta, Alfredo Tartarone, Aldo Pezzuto, Antonella Facchinetti, Daniele Santini, Paola Ulivi, et al. "A fully automated assay to detect the expression of pan-cytokeratins and of EML4-ALK fusion protein in circulating tumour cells (CTCs) predicts outcome of non-small cell lung cancer (NSCLC) patients." Translational Lung Cancer Research 10, no. 1 (January 2021): 80–92. http://dx.doi.org/10.21037/tlcr-20-855.
Повний текст джерелаManjon, Nuria, Jaime Martinez, Gonzalo Garcia, Ana Aragon, Jaime Carrillo, Jose Luis Rodriguez-Peralto, Jose Ramón Antunez Lopez, Javier Hernandez-Losa, Rosario Cospedal, and Maria Luisa Villahermosa. "A new diagnostic method based on RT-PCR and CLART technology for non-small cell lung cancer (NSCLC) to detect major EML4-ALK and ROS.1 translocations: CLART CMA ALK and ROS.1." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): e20045-e20045. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e20045.
Повний текст джерелаLi, Bin, Yongbin Hu, Qiongzhi He, Jingchen Lu, Gengwen Huang, and Sheng Xiao. "Loss of 5'ALK leads to better response to crizotinib in sarcomas with ALK rearrangement." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): e23554-e23554. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e23554.
Повний текст джерелаSmolle, Elisabeth, Valentin Taucher, Joerg Lindenmann, Philipp J. Jost, and Martin Pichler. "Current Knowledge about Mechanisms of Drug Resistance against ALK Inhibitors in Non-Small Cell Lung Cancer." Cancers 13, no. 4 (February 9, 2021): 699. http://dx.doi.org/10.3390/cancers13040699.
Повний текст джерелаWatanabe, Satoshi, Kazuko Sakai, Naoya Matsumoto, Jun Koshio, Akira Ishida, Tetsuya Abe, Daisuke Ishikawa, et al. "Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)." Cancers 15, no. 1 (December 29, 2022): 204. http://dx.doi.org/10.3390/cancers15010204.
Повний текст джерелаProia, David A., Jaime Acquaviva, Qin Jiang, Liquan Xue, Donald Smith, Julie C. Friedland, Suqin He, Jim Sang, Stephan Morris, and Yumiko Wada. "Preclinical activity of the Hsp90 inhibitor, ganetespib, in ALK- and ROS1-driven cancers." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 3090. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.3090.
Повний текст джерелаLi, Yongjun, Xiaofen Ye, Jinfeng Liu, Jiping Zha, and Lin Pei. "Evaluation of EML4-ALK Fusion Proteins in Non–Small Cell Lung Cancer Using Small Molecule Inhibitors." Neoplasia 13, no. 1 (January 2011): 1—IN1. http://dx.doi.org/10.1593/neo.101120.
Повний текст джерелаO'Regan, Laura, Giancarlo Barone, Rozita Adib, Chang Gok Woo, Hui Jeong Jeong, Emily L. Richardson, Mark W. Richards, et al. "EML4–ALK V3 oncogenic fusion proteins promote microtubule stabilization and accelerated migration through NEK9 and NEK7." Journal of Cell Science 133, no. 9 (March 17, 2020): jcs241505. http://dx.doi.org/10.1242/jcs.241505.
Повний текст джерелаXu, Chunwei, Wen-xian Wang, Meiyu Fang, Yan-ping Chen, Yu Chen, Li-hua Zhong, Fang-fang Chen, et al. "Parallel VENTANA IHC and RT-PCR of ALK status in non-small cell lung cancer and response to crizotinib." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): 11623. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.11623.
Повний текст джерела